Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)

计划入组 804 人 · 首次发布于 2017 年 2 月 2 日

A Safety Study of an Oral EGFR Inhibitor, AV-412, Administered Three Times Weekly in Advanced Solid Tumor Patients

计划入组 37 人 · 首次发布于 2007 年 10 月 31 日

Safety/Tolerability Study of AV-412 in Subjects With Refractory or Relapsed Solid Tumor Malignancies

计划入组 27 人 · 首次发布于 2006 年 9 月 28 日

OTS-412

AV-412

C₄₁H₄₄ClFN₆O₇S₂

AD-412

Accession Therapeutics Limited

United Kingdom

Cortice Biosciences, Inc.

United States

Noordwest Ziekenhuisgroep

Netherlands

Keytruda Fails Phase 3 Trial in Early-Stage Head and Neck Cancer

Innovative Trial Designs Emerge After Immunotherapy Setbacks in Head and Neck Cancer

Merck Discontinues Phase 3 Trials of Pembrolizumab in NSCLC and CSCC